NASDAQ · PRLD
Healthcare · Biotechnology
$6.34
Down-$0.59 (-9.31%)
Updated Aug 28, 2026, 5:38 PM
SID Score
6.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
PRLD closed at $6.34 after 21 trading sessions, up 25.54% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $6.48 | $6.61 | $6.21 | $6.34 | 364.18K |
| Aug 26, 2026 | $6.61 | $6.71 | $6.3701 | $6.56 | 466.28K |
| Aug 25, 2026 | $6.57 | $6.695 | $6.31 | $6.59 | 415.48K |
| Aug 24, 2026 | $6.64 | $6.83 | $6.115 | $6.47 | 515.72K |
| Aug 21, 2026 | $6.56 | $6.8162 | $6.40 | $6.63 | 519.21K |
| Aug 20, 2026 | $5.70 | $6.6496 | $5.70 | $6.50 | 2.44M |
| Aug 19, 2026 | $5.84 | $5.90 | $5.66 | $5.78 | 421.55K |
| Aug 18, 2026 | $5.62 | $5.78 | $5.485 | $5.75 | 268.55K |
| Aug 17, 2026 | $5.57 | $5.86 | $5.45 | $5.63 | 265.43K |
| Aug 14, 2026 | $5.45 | $5.61 | $5.15 | $5.55 | 452.14K |
| Aug 13, 2026 | $5.77 | $5.91 | $5.21 | $5.36 | 888.27K |
| Aug 12, 2026 | $5.39 | $5.8973 | $5.39 | $5.73 | 623.88K |
| Aug 11, 2026 | $4.95 | $5.85 | $4.83 | $5.32 | 698.44K |
| Aug 10, 2026 | $4.91 | $5.00 | $4.81 | $4.83 | 217.17K |
| Aug 7, 2026 | $4.74 | $4.915 | $4.63 | $4.90 | 165.7K |
| Aug 6, 2026 | $4.47 | $4.75 | $4.47 | $4.68 | 242.34K |
| Aug 5, 2026 | $4.51 | $4.595 | $4.37 | $4.54 | 158.28K |
| Aug 4, 2026 | $4.41 | $4.58 | $4.405 | $4.52 | 218.84K |
| Aug 3, 2026 | $4.65 | $4.65 | $4.35 | $4.39 | 288.74K |
| Jul 31, 2026 | $5.03 | $5.15 | $4.57 | $4.60 | 292.74K |
| Jul 30, 2026 | $4.71 | $5.13 | $4.71 | $5.05 | 329.78K |
The latest Smart Investors Daily articles mentioning PRLD.
PRLD research
Company profile and research snapshot.
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 29, 2026 | HC Wainwright & Co. | Buy | — |
| May 4, 2026 | D. Boral Capital | Buy | — |
| Apr 27, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 11, 2026 | Citizens | Market Outperform | — |
| Sep 23, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Feb 26, 2026
Sana Biotechnology Inc. (NASDAQ:SANA) is one of the most promising penny stocks under $5 to buy. On February 17, Sana Biotechnology appointed Brian Piper as Executive Vice President and Chief Financial Officer. Brian Piper joined the company with over 25 years of biopharmaceutical experience, most recently serving as CFO of Scorpion Therapeutics and its spin-off, […]
Benzinga · Feb 3, 2026
Benzinga · Feb 3, 2026
GlobeNewswire Inc. · Dec 6, 2025
Prelude Therapeutics presented preclinical data on two promising therapeutic approaches for myeloproliferative neoplasms (MPNs): a JAK2V617F-selective JH2 inhibitor (PRT12396) and a mutant calreticulin targeted degrader antibody conjugate, demonstrating potential disease-modifying capabilities.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PRLD.
